http://www.sohu.com/a/311549186_711825?spm=smpc.home.top-news4.1.1556861982607ejnqiha
起底步长制药金融帝国：靠给新加坡人扎针挖第一桶金
大猫财经
1003文章 3.1亿总阅读
查看TA的文章>
1419
起底步长制药金融帝国：靠给人扎针挖第一桶金，明星药26次被预警
2019-05-03 08:25 美的 /年报 /推广
来源| 重庆晨报
有中国亿万富翁家庭花650万美元让孩子入学斯坦福大学，媒体指出该高价入学事件当事人为该校学生赵雨思其父亲为步长制药公司董事长赵涛。
据报道，赵涛通过摩根士丹利的经理与升学辅导咨询师辛格见面，随后赵涛向辛格支付了650万美元，赵雨思于2017年被美国斯坦福大学录取，主修心理学和东亚研究。
2017年底，辛格伪造了信息让申请者拥有帆船运动的证书，并顺利进入斯坦福大学。在赵雨思入学以后，辛格捐助了帆船项目50万美元，这笔资金可以由帆船教练约翰·范德莫尔随意支配。
斯坦福大学在3月底已将赵雨思开除，教练也已被抓，目前斯坦福大学拒绝对该事件发表评论。这是美国大学入学舞弊案迄今为止最大的一笔。
2日，媒体就此事向步长制药副总裁、董事会秘书蒲晓平进行求证，蒲晓平回应称正在研究这件事，他表示步长制药“是一家正常经营的公司，大股东和我们关联性不是很强的，上交所还没有问询我们，一切以公告为准”。
01
步长创业的第一桶金：给新加坡病人扎针
公开资料显示，赵涛为步长制药公司董事长，现年53岁，新加坡籍，2001年起任公司董事长，现兼任步长(香港)董事、首诚国际(香港)董事和大得控股董事等职务。
步长制药成立于1993年，于2016年11月18日上市，是一家山东的医药公司，同时也是“家族企业”，属于父子共同创业。赵步长(著名心血管病专家、著名药物发明家、步长脑心通发明人)是赵涛的父亲，赵超(现任步长制药总裁)是赵步长的二儿子。步长制药主要从事中成药的研发、生产和销售，主要产品涉及心脑血管疾病中成药领域，也覆盖妇科用药等其他领域。
赵步长出生于1942年，西安交通大学医学院(原西安医学院)毕业后，他响应号召，自愿报名来到位于中苏交界的新疆阿勒泰支边。1963年的夏天，赵步长动员妻子伍海勤也一起来到茫茫的荒漠戈壁，二人在新疆整整工作了18年后，才调回咸阳核工业部215医院，做一名普通的大夫。他们俩的四个儿女，都是在新疆出生。
彼时，赵步长将中风、冠心病作为研究的主攻方向，治疗中风偏瘫上，创建了“药气针”疗法和“脑心同治”理论，并在1992年成为享受国务院特殊津贴的专家。
与“一代打天下、二代继承衣钵”的许多家族企业不同，步长制药的最早发展，却是由赵步长父子三人合力缔造，二代也就是创一代，即上阵父子兵。
1966年出生的赵涛，与父母赵步长、伍海勤一样，也是学医出身，1989年毕业于西安医科大。赵步长治疗心脑血管病患者的“药气针”技术，其实是父子二人潜心研究的成果。赵氏父子创办步长制药的启动资金从哪儿来呢？这还得说一段“中国神针”风靡新加坡的故事。
1992年冬，赵涛与父亲一起受邀参加在新加坡举办的“中医与针灸走向世界国际学术研讨会”。 会议期间，主办方特意为赵家父子安排一场现场诊疗活动。那时，一名叫刘亚美的新加坡女患者，60多岁，已瘫痪六年，双腿完全不能动弹。
在全场专家和记者长枪短炮的注视下，赵涛给那位老人戴上特制的药帽，按摩头部片刻之后，取出银针向刘亚美四肢上的穴位扎去……
20分钟后，奇迹出现了！刘亚美竟然能抓住扶手慢慢站了起来。第二天，新加坡的大小报纸纷纷刊登“中国神针”成功诊疗消息，赵家父子成了新加坡家喻户晓的中医名人。应当地恳请，赵涛留在新加坡继续行医。
当赵步长从新加坡回来，却发现自己居然被单位“优化组合”掉了！1993年2月，赵步长和妻子伍海勤被双双除名，而他们治疗心脑血管疾病的“脑心通”胶囊，也到了科研攻关的关键时期。
无奈之下，赵步长与远在新加坡的儿子赵涛通上电话，最终决定自主创业。1993年8月28日，步长制药有限公司在咸阳宣告成立，企业性质是“中外合资企业”，启动资金就是赵涛汇回的40万美金。原来，三个月的新加坡行医，让27岁的赵涛足足赚了90万美金。
创业次年，首款独家专利药产品“步长脑心通”一投放市场，当年就卖了500万元，之后，这个“爆款”产品更是一路狂飙突进，如今，它与地奥心血康、天士力复方丹参滴丸一并雄踞心脑血管中成药三大品牌行列。
2016年11月18日，总部位于山东菏泽的步长制药在上交所上市，按当日市值计算，步长赵氏家族的财富达到284.81亿元，成为了年度山东首富。
02
步长家族“十人团” 不成功就要饭
作为赵步长的大儿子，赵涛是步长制药的联合创始人，当年在咸阳的公司执照，是他一手经办的；步长的LOGO，还是他在寄给父亲的一张明信片上勾画的，还留下一句话：总有一天，全世界会记住它。
在步长创办过程中，大家族赵步长就像指挥千军万马的司令官，初创时，其实是他与大儿子赵涛的“二人转”，当企业上规模后，就开始向家族成员“招兵买马”，扩充创业队伍。二儿子赵超，现任步长制药总裁，毕业后在黄河啤酒厂任生产科长，父亲一喊，就摔破了自己的铁饭碗，参与进来。还有，小女儿赵菁，目前是集团旗下山东丹红制药董事长，学医的她也是辞掉公职加盟进来。
不仅如此，赵涛、赵超两兄弟的媳妇，还有大女儿赵骅和她妹妹赵菁的夫婿，也都在步长任职，一家二代人组成了家族“十人团”，时年55岁的赵步长说，我们没有退路，“不成功就要饭！”
上市1年多以后，12月11日，顶着“最贵新股”光环的步长制药跌破了发行价，成为2016年IPO新规实施以来首个跌破发行价的个股。相对高峰时，步长制药的市值蒸发近700亿元，赵氏家族财富“大缩水”。
03
四大产品每年带来近百亿收入
数据显示，该公司心脑血管相关的产品包括了中成药丹红注射液、脑心通胶囊、稳心颗粒以及化学药谷红注射液，2017年合计收入达99.44亿元，增长率为11.76%。四大产品治疗范围涵盖中风、心律失常、供血不足和缺血梗塞等常见心脑血管疾病。
近日，步长制药披露2018年年报，公司去年实现营业收入136.6亿元，同比下降1.4%，但实现归属于上市公司股东的净利润为18.9亿元，同比增长15.3%。2019年一季度公司实现营业总收入28.83亿，同比增长18.61%；归属于母公司所有者的净利润2.84亿，同比增长37.79%。其中，心脑血管领域2018年营收近110亿元，占比超80%，毛利率为85.16%，公司的四种主要心脑血管药物产品2018年合计收入91.43亿元。
● 资料显示，步长制药近年又培育出了灯盏花素氯化钠注射液(独家生产)，治疗范围包括：缺血性脑血管疾病，如脑梗塞，脑出血后遗症所致偏瘫；冠心病、心绞痛、心肌梗塞及高粘血症等；和其他缺血性及伴有微循环障碍性疾病。该产品2018年的收入为0.26亿元。
● 在化药领域，公司培育出了参芎葡萄糖注射液，用于闭塞性脑血管疾病及其他缺血性血管疾病。该品种2018年的收入为2.84亿元。
● 复方脑肽节苷脂注射液(独家、专利品种)，用于治疗脑卒中、老年性痴呆，颅脑损伤、脊髓损伤及创伤性周围神经损伤，用于治疗脑部疾病引起的功能障碍。该品种2018年的收入为5.05亿元。
● 复方曲肽注射液(独家、专利品种)，用于治疗脑卒中等急慢性脑血管疾病，老年性痴呆，颅脑外伤、脊髓损伤等原因引起的中枢神经损伤、周围神经损伤、脑血管意外创伤及创伤后的神经系统后遗症，以及脑血管疾病引起的脑功能障碍等后遗症；用于治疗闭塞综合征、动脉硬化、血栓性静脉炎、毛细血管出血以及血管通透性升高引起的水肿。该品种2018年的收入为3.55亿元。
● 银杏蜜环口服溶液(独家、专利品种)，主要用于冠心病、心绞痛、缺血性脑血管疾病，可改善心、脑缺血性症状。该品种2018年的收入为2.79亿元。
04
丹红注射液曾26次被预警列入重点监控
据媒体2018年4月报道，步长制药的丹红注射液(卖60元一支)因频发严重不良反应，26次被预警列入重点监控，甚至随时面临停用风险。
根据步长制药上市前的招股说明书，在2013年至2015年期间，丹红注射液的年销售金额分别高达41.61亿、38.31亿和33.6亿，合计113.52亿。收入占比超过30%，利润占比更稳居40%以上。
报道称，当时19个省份和15个城市出台的重点监控药品和辅助用药目录中中药品种占比接近40%，其中九成是中药注射剂。步长制药的独家专利产品——丹红注射液，首当其冲，被梳理出至少在11个省(市)26次被预警(严格监控)、限制使用，甚至随时面临停用风险。
05
2015年平均每天花1600万元“推广”
据媒体报道，2016年年中，步长制药重启IPO，却被媒体爆出“天价推广费”——2013年至2015年的三年间，公司在“市场及学术推广”方面分别花去了44.66亿、51.83亿、58.41亿，累计达到154.9亿元，连续三年超过同期营业收入的一半以上。其中2015年，平均每天花1600万元用于“推广”。
据时代周报2016年报道，招股说明书显示，报告期内，“市场及学术推广费”占当年营业收入的比重超过了50%，是当期研发费用的20余倍。
返回搜狐，查看更多
声明：该文观点仅代表作者本人，搜狐号系信息发布平台，搜狐仅提供信息存储空间服务。
Big cat finance
1003 article
3.1 billion total reading
View TA's article >
1419
share to
The bottom step of the pharmaceutical financial empire: relying on the needle to dig the first bucket of gold, star medicine 26 times was warned
2019-05-03 08:25 beautiful / annual report / promotion
Source | Chongqing Morning News
A Chinese billionaire family spent $6.5 million to enroll their children at Stanford University. The media pointed out that the high-priced school attendance was for the school's student Zhao Yusi, whose father was Zhao Tao, chairman of Stephan Pharmaceuticals.
According to reports, Zhao Tao met with Singh, the manager of Morgan Stanley, and the counseling counselor of Singh, and then Zhao Tao paid $6.5 million to Singh. Zhao Yusi was admitted to Stanford University in 2017, majoring in psychology and East Asian studies. .
At the end of 2017, Singer forged information to give applicants a certificate of sailing and successfully entered Stanford University. After Zhao Yusi entered the school, Singh donated 500,000 US dollars for the sailing project, which can be arbitrarily controlled by sailing coach John Vandermore.
Stanford University has expelled Zhao Yusi at the end of March, and the coach has also been arrested. Currently Stanford University declined to comment on the incident. This is by far the largest number of college fraud cases in the United States.
On the 2nd, the media conducted a verification on the matter to Pu Xiaoping, vice president of the pharmaceutical company and secretary of the board of directors. Pu Xiaoping responded that he was studying the matter. He said that Buchang Pharmaceutical is “a normal company, and the major shareholder is not very relevant to us. The Shanghai Stock Exchange has not asked us yet, and everything is subject to the announcement."
01
The first bucket of gold for step entrepreneurship: giving Singapore patients a needle
According to public information, Zhao Tao is the chairman of Buchang Pharmaceutical Co., a 53-year-old Singaporean. He has been the chairman of the company since 2001. He is also a director of the step (Hong Kong), a director of Shoucheng International (Hong Kong) and a director of Dad Holdings. Waiting for a position.
Founded in 1993, Buchang Pharmaceutical was listed on November 18, 2016. It is a Shandong pharmaceutical company and a “family company”. It belongs to the father and son to start a business together. Zhao Buchang (famous cardiovascular disease expert, famous drug inventor, stepper brain heart inventor) is Zhao Tao's father, Zhao Chao (currently president of Buchang Pharmaceutical) is the second son of Zhao Buchang. Buchang Pharmaceutical is mainly engaged in the research and development, production and sales of proprietary Chinese medicines. The main products are in the field of traditional Chinese medicine for cardiovascular and cerebrovascular diseases, as well as other fields such as gynecological medication.
Zhao Buchang was born in 1942. After graduating from Xi'an Jiaotong University School of Medicine (formerly Xi'an Medical College), he responded to the call and voluntarily signed up to the Altay branch in Xinjiang on the border between China and the Soviet Union. In the summer of 1963, Zhao Buchang mobilized his wife Wu Haiqin to come to the deserted Gobi. After two 18 years of work in Xinjiang, they returned to the 215 Hospital of Xianyang Nuclear Industry Department to become an ordinary doctor. The four children of both of them were born in Xinjiang.
At that time, Zhao Buchang took stroke and coronary heart disease as the main direction of research, treated stroke hemiplegia, and created the theory of "medicine gas needle" therapy and "Heart and Heart Tongzhi". In 1992, he became an expert enjoying special allowances from the State Council.
Unlike many family businesses that "one generation fights the world and the second generation inherits the clothes", the earliest development of Buchang Pharmaceutical was created by the three fathers and sons of Zhao Buchang. The second generation is also a generation, that is, the father and son.
Born in 1966, Zhao Tao, like his parents Zhao Buchang and Wu Haiqin, was also a medical doctor. He graduated from Xi'an Medical University in 1989. Zhao Buchang's "medicine gas needle" technology for patients with cardiovascular and cerebrovascular diseases is actually the result of painstaking research by father and son. Where did the starting capital of Zhao’s father and son founded Buchang Pharmaceutical come from? This also has to say that a "Chinese god" is popular in Singapore.
In the winter of 1992, Zhao Tao and his father were invited to participate in the "International Symposium on Chinese Medicine and Acupuncture to the World" held in Singapore. During the meeting, the organizers specially arranged an on-site medical treatment for the Zhao family. At that time, a Singaporean female patient named Liu Yamei, who was in her 60s, had been in her for six years and could not move her legs at all.
Under the watchful eyes of the audience experts and reporters, Zhao Tao put a special medicine cap on the old man. After massaging the head for a while, he took out the silver needle and poked it on the acupoints of Liu Yamei's limbs...
After 20 minutes, the miracle appeared! Liu Yamei was able to grab the handrail and slowly stood up. The next day, Singapore's large and small newspapers published "Chinese God" successful medical treatment news, Zhao family and son became Singapore's well-known Chinese medicine celebrities. Should be requested, Zhao Tao stayed in Singapore to continue practicing medicine.
When Zhao Buchang came back from Singapore, he found that he was actually "optimized combination" by the unit! In February 1993, Zhao Buchang and his wife Wu Haiqin were both removed, and their "Brain Heart Pass" capsules for treating cardiovascular and cerebrovascular diseases also reached a critical period for scientific research.
In desperation, Zhao Buchang and his son Zhao Tao, who is far away in Singapore, called and decided to start their own business. On August 28, 1993, Buchang Pharmaceutical Co., Ltd. was established in Xianyang. The nature of the enterprise was “Sino-foreign joint venture”, and the starting capital was the 400,000 US dollars that Zhao Tao remitted. It turned out that three months of practicing medicine in Singapore, 27-year-old Zhao Tao made a full profit of 900,000 dollars.
In the second year of the business, the first exclusive patented drug product, “Step by Brain Heart Pass”, was put on the market. In the same year, it sold for 5 million yuan. After that, this “explosive model” product was rushing all the way. Today, it is related to the Olympics and the Tianshili. Compound Danshen Dripping Pills are among the top three brands of cardiovascular and cerebrovascular medicine.
On November 18, 2016, Buchang Pharmaceutical Co., Ltd., headquartered in Heze, Shandong, was listed on the Shanghai Stock Exchange. According to the market value of the day, the wealth of the Zhao family reached 24.478 billion yuan, becoming the richest person in Shandong.
02
Step family, "ten group", unsuccessful meal
As the eldest son of Zhao Buchang, Zhao Tao is the co-founder of Buchang Pharmaceutical. He was the manager of the company in Xianyang. He was the one who handled it. The logo of the step was drawn on a postcard sent to his father. Also left a sentence: one day, the world will remember it.
In the process of establishing the step, the big family Zhao Buchang was like the commander of the commander of the army. When he first started, he was actually the "two-person turn" between him and his eldest son Zhao Tao. When the company was on the scale, it began to recruit soldiers from the family members. ", expand the entrepreneurial team. The second son, Zhao Chao, is the current president of Buchang Pharmaceutical. After graduation, he worked as a production chief at the Yellow River Brewery. When his father shouted, he broke his iron rice bowl and participated. Also, the youngest daughter, Zhao Jing, is currently the chairman of the Shandong Danhong Pharmaceutical Group. She is also a doctor who quit her job.
Not only that, the daughters of Zhao Tao and Zhao Chao’s brothers, as well as the eldest daughter Zhao Wei and her sister Zhao Jing’s husband, also served in the step, a second generation formed the family “ten group”. Zhao Buchang, 55, said that we have no retreat. "If you don't succeed, you have to eat!"
After more than one year of listing, on December 11, Stephan Pharmaceutical, which was the "most expensive new stock" aura, fell below the issue price and became the first stock to break the issue price since the implementation of the new IPO in 2016. At the relative peak, the market value of Buchang Pharmaceutical evaporated nearly 70 billion yuan, and the wealth of the Zhao family was “shrinking”.
03
Four major products bring nearly 10 billion in revenue every year
The data show that the company's cardiovascular and cerebrovascular related products include Chinese patent medicine Danhong injection, Naoxintong capsule, Wenxin granules and chemical medicine Guhong injection. The total income in 2017 reached 9.944 billion yuan, with a growth rate of 11.76%. . The four major product treatments cover common cardiovascular and cerebrovascular diseases such as stroke, arrhythmia, insufficient blood supply and ischemic infarction.
Recently, Buchang Pharmaceutical disclosed its annual report for 2018. The company achieved operating income of 13.66 billion yuan last year, down 1.4% year-on-year, but the net profit attributable to shareholders of listed companies was 1.89 billion yuan, a year-on-year increase of 15.3%. In the first quarter of 2019, the company achieved a total operating income of 2.883 billion, an increase of 18.61% year-on-year; the net profit attributable to owners of the parent company was 284 million, an increase of 37.79%. Among them, the cardiovascular and cerebrovascular field in the 2018 revenue of nearly 11 billion yuan, accounting for more than 80%, gross margin of 85.16%, the company's four major cardiovascular and cerebrovascular drug products in 2018 total income of 9.143 billion yuan.
● According to the data, Stephan Pharmaceutical has developed breviscapine sodium chloride injection (exclusive production) in recent years. The treatment scope includes: ischemic cerebrovascular disease, such as cerebral infarction, hemiplegia caused by sequelae of cerebral hemorrhage; coronary heart disease, Angina, myocardial infarction and hyperviscosity; and other ischemic and microcirculatory disorders. The product's revenue in 2018 is 0.26 billion yuan.
● In the field of chemical medicine, the company has developed Glucosamine Injection for occlusive cerebrovascular disease and other ischemic vascular diseases. The income of this variety in 2018 was 284 million yuan.
● Compound brain peptide ganglioside injection (exclusive, patented variety) for the treatment of stroke, senile dementia, craniocerebral injury, spinal cord injury and traumatic peripheral nerve injury, for the treatment of dysfunction caused by brain diseases. The income of this variety in 2018 is 505 million yuan.
● Compound Quartz Injection (exclusive, patented variety) for the treatment of acute and chronic cerebrovascular diseases, senile dementia, craniocerebral trauma, spinal cord injury and other causes of central nervous system injury, peripheral nerve injury, cerebrovascular accident Nervous sequelae after trauma and trauma, and sequelae such as brain dysfunction caused by cerebrovascular disease; used to treat edema caused by occlusion syndrome, arteriosclerosis, thrombophlebitis, capillary hemorrhage, and elevated vascular permeability. The income of this variety in 2018 is 355 million yuan.
● Ginkgo biloba oral solution (exclusive, patented variety), mainly used for coronary heart disease, angina pectoris, ischemic cerebrovascular disease, can improve heart and cerebral ischemic symptoms. The income of this variety in 2018 was 279 million yuan.
04
Danhong injection has been listed as key monitoring for 26 times.
According to the media reported in April 2018, Buhong Pharmaceutical's Danhong injection (selling 60 yuan a) was frequently listed as a key monitoring due to frequent serious adverse reactions, and even faced the risk of suspension at any time.
According to the prospectus before the listing of Stephan Pharmaceutical, the annual sales amount of Danhong Injection was as high as 4.161 billion, 3.831 billion and 3.36 billion, totaling 11.352 billion from 2013 to 2015. The proportion of revenue is over 30%, and the proportion of profit is more than 40%.
According to the report, the list of Chinese medicines in the list of key monitoring drugs and auxiliary medicines issued by 19 provinces and 15 cities accounted for nearly 40%, of which 90% were Chinese medicine injections. Stephan Pharmaceutical's exclusive patented product, Danhong Injection, bears the brunt of it and is sorted out at least 11 provinces (cities) for 26 warnings (strictly monitored), restricted use, and even at risk of decommissioning at any time.
05
In 2015, the average daily spending of 16 million yuan "promotion"
According to media reports, in the middle of 2016, Buchang Pharmaceutical restarted the IPO, but it was exploded by the media with “astronomical promotion fee”. During the three years from 2013 to 2015, the company spent 44.66 on “market and academic promotion”. 100 million yuan, 5.183 billion yuan, 5.941 billion yuan, a total of 15.49 billion yuan, more than half of the operating income for the third consecutive year. In 2015, an average of 16 million yuan was spent on “promotion” every day.
According to the Times Weekly report in 2016, the prospectus shows that during the reporting period, “market and academic promotion fees” accounted for more than 50% of the operating income of the year, and more than 20 times of the current research and development expenses.
Go back to Sohu and see more
Disclaimer: This article only represents the author himself, Sohu is the information publishing platform, and Sohu only provides information storage space services.
起底步长制药金融帝国：靠给新加坡人扎针挖第一桶金
大猫财经
1003文章 3.1亿总阅读
查看TA的文章>
1419
- 分享到
起底步长制药金融帝国：靠给人扎针挖第一桶金，明星药26次被预警
2019-05-03 08:25 美的 /年报 /推广
来源| 重庆晨报
有中国亿万富翁家庭花650万美元让孩子入学斯坦福大学，媒体指出该高价入学事件当事人为该校学生赵雨思其父亲为步长制药公司董事长赵涛。
据报道，赵涛通过摩根士丹利的经理与升学辅导咨询师辛格见面，随后赵涛向辛格支付了650万美元，赵雨思于2017年被美国斯坦福大学录取，主修心理学和东亚研究。
2017年底，辛格伪造了信息让申请者拥有帆船运动的证书，并顺利进入斯坦福大学。在赵雨思入学以后，辛格捐助了帆船项目50万美元，这笔资金可以由帆船教练约翰·范德莫尔随意支配。
斯坦福大学在3月底已将赵雨思开除，教练也已被抓，目前斯坦福大学拒绝对该事件发表评论。这是美国大学入学舞弊案迄今为止最大的一笔。
2日，媒体就此事向步长制药副总裁、董事会秘书蒲晓平进行求证，蒲晓平回应称正在研究这件事，他表示步长制药“是一家正常经营的公司，大股东和我们关联性不是很强的，上交所还没有问询我们，一切以公告为准”。
01
步长创业的第一桶金：给新加坡病人扎针
公开资料显示，赵涛为步长制药公司董事长，现年53岁，新加坡籍，2001年起任公司董事长，现兼任步长(香港)董事、首诚国际(香港)董事和大得控股董事等职务。
步长制药成立于1993年，于2016年11月18日上市，是一家山东的医药公司，同时也是“家族企业”，属于父子共同创业。赵步长(著名心血管病专家、著名药物发明家、步长脑心通发明人)是赵涛的父亲，赵超(现任步长制药总裁)是赵步长的二儿子。步长制药主要从事中成药的研发、生产和销售，主要产品涉及心脑血管疾病中成药领域，也覆盖妇科用药等其他领域。
赵步长出生于1942年，西安交通大学医学院(原西安医学院)毕业后，他响应号召，自愿报名来到位于中苏交界的新疆阿勒泰支边。1963年的夏天，赵步长动员妻子伍海勤也一起来到茫茫的荒漠戈壁，二人在新疆整整工作了18年后，才调回咸阳核工业部215医院，做一名普通的大夫。他们俩的四个儿女，都是在新疆出生。
彼时，赵步长将中风、冠心病作为研究的主攻方向，治疗中风偏瘫上，创建了“药气针”疗法和“脑心同治”理论，并在1992年成为享受国务院特殊津贴的专家。
与“一代打天下、二代继承衣钵”的许多家族企业不同，步长制药的最早发展，却是由赵步长父子三人合力缔造，二代也就是创一代，即上阵父子兵。
1966年出生的赵涛，与父母赵步长、伍海勤一样，也是学医出身，1989年毕业于西安医科大。赵步长治疗心脑血管病患者的“药气针”技术，其实是父子二人潜心研究的成果。赵氏父子创办步长制药的启动资金从哪儿来呢？这还得说一段“中国神针”风靡新加坡的故事。
1992年冬，赵涛与父亲一起受邀参加在新加坡举办的“中医与针灸走向世界国际学术研讨会”。 会议期间，主办方特意为赵家父子安排一场现场诊疗活动。那时，一名叫刘亚美的新加坡女患者，60多岁，已瘫痪六年，双腿完全不能动弹。
在全场专家和记者长枪短炮的注视下，赵涛给那位老人戴上特制的药帽，按摩头部片刻之后，取出银针向刘亚美四肢上的穴位扎去……
20分钟后，奇迹出现了！刘亚美竟然能抓住扶手慢慢站了起来。第二天，新加坡的大小报纸纷纷刊登“中国神针”成功诊疗消息，赵家父子成了新加坡家喻户晓的中医名人。应当地恳请，赵涛留在新加坡继续行医。
当赵步长从新加坡回来，却发现自己居然被单位“优化组合”掉了！1993年2月，赵步长和妻子伍海勤被双双除名，而他们治疗心脑血管疾病的“脑心通”胶囊，也到了科研攻关的关键时期。
无奈之下，赵步长与远在新加坡的儿子赵涛通上电话，最终决定自主创业。1993年8月28日，步长制药有限公司在咸阳宣告成立，企业性质是“中外合资企业”，启动资金就是赵涛汇回的40万美金。原来，三个月的新加坡行医，让27岁的赵涛足足赚了90万美金。
创业次年，首款独家专利药产品“步长脑心通”一投放市场，当年就卖了500万元，之后，这个“爆款”产品更是一路狂飙突进，如今，它与地奥心血康、天士力复方丹参滴丸一并雄踞心脑血管中成药三大品牌行列。
2016年11月18日，总部位于山东菏泽的步长制药在上交所上市，按当日市值计算，步长赵氏家族的财富达到284.81亿元，成为了年度山东首富。
02
步长家族“十人团” 不成功就要饭
作为赵步长的大儿子，赵涛是步长制药的联合创始人，当年在咸阳的公司执照，是他一手经办的；步长的LOGO，还是他在寄给父亲的一张明信片上勾画的，还留下一句话：总有一天，全世界会记住它。
在步长创办过程中，大家族赵步长就像指挥千军万马的司令官，初创时，其实是他与大儿子赵涛的“二人转”，当企业上规模后，就开始向家族成员“招兵买马”，扩充创业队伍。二儿子赵超，现任步长制药总裁，毕业后在黄河啤酒厂任生产科长，父亲一喊，就摔破了自己的铁饭碗，参与进来。还有，小女儿赵菁，目前是集团旗下山东丹红制药董事长，学医的她也是辞掉公职加盟进来。
不仅如此，赵涛、赵超两兄弟的媳妇，还有大女儿赵骅和她妹妹赵菁的夫婿，也都在步长任职，一家二代人组成了家族“十人团”，时年55岁的赵步长说，我们没有退路，“不成功就要饭！”
上市1年多以后，12月11日，顶着“最贵新股”光环的步长制药跌破了发行价，成为2016年IPO新规实施以来首个跌破发行价的个股。相对高峰时，步长制药的市值蒸发近700亿元，赵氏家族财富“大缩水”。
03
四大产品每年带来近百亿收入
数据显示，该公司心脑血管相关的产品包括了中成药丹红注射液、脑心通胶囊、稳心颗粒以及化学药谷红注射液，2017年合计收入达99.44亿元，增长率为11.76%。四大产品治疗范围涵盖中风、心律失常、供血不足和缺血梗塞等常见心脑血管疾病。
近日，步长制药披露2018年年报，公司去年实现营业收入136.6亿元，同比下降1.4%，但实现归属于上市公司股东的净利润为18.9亿元，同比增长15.3%。2019年一季度公司实现营业总收入28.83亿，同比增长18.61%；归属于母公司所有者的净利润2.84亿，同比增长37.79%。其中，心脑血管领域2018年营收近110亿元，占比超80%，毛利率为85.16%，公司的四种主要心脑血管药物产品2018年合计收入91.43亿元。
● 资料显示，步长制药近年又培育出了灯盏花素氯化钠注射液(独家生产)，治疗范围包括：缺血性脑血管疾病，如脑梗塞，脑出血后遗症所致偏瘫；冠心病、心绞痛、心肌梗塞及高粘血症等；和其他缺血性及伴有微循环障碍性疾病。该产品2018年的收入为0.26亿元。
● 在化药领域，公司培育出了参芎葡萄糖注射液，用于闭塞性脑血管疾病及其他缺血性血管疾病。该品种2018年的收入为2.84亿元。
● 复方脑肽节苷脂注射液(独家、专利品种)，用于治疗脑卒中、老年性痴呆，颅脑损伤、脊髓损伤及创伤性周围神经损伤，用于治疗脑部疾病引起的功能障碍。该品种2018年的收入为5.05亿元。
● 复方曲肽注射液(独家、专利品种)，用于治疗脑卒中等急慢性脑血管疾病，老年性痴呆，颅脑外伤、脊髓损伤等原因引起的中枢神经损伤、周围神经损伤、脑血管意外创伤及创伤后的神经系统后遗症，以及脑血管疾病引起的脑功能障碍等后遗症；用于治疗闭塞综合征、动脉硬化、血栓性静脉炎、毛细血管出血以及血管通透性升高引起的水肿。该品种2018年的收入为3.55亿元。
● 银杏蜜环口服溶液(独家、专利品种)，主要用于冠心病、心绞痛、缺血性脑血管疾病，可改善心、脑缺血性症状。该品种2018年的收入为2.79亿元。
04
丹红注射液曾26次被预警列入重点监控
据媒体2018年4月报道，步长制药的丹红注射液(卖60元一支)因频发严重不良反应，26次被预警列入重点监控，甚至随时面临停用风险。
根据步长制药上市前的招股说明书，在2013年至2015年期间，丹红注射液的年销售金额分别高达41.61亿、38.31亿和33.6亿，合计113.52亿。收入占比超过30%，利润占比更稳居40%以上。
报道称，当时19个省份和15个城市出台的重点监控药品和辅助用药目录中中药品种占比接近40%，其中九成是中药注射剂。步长制药的独家专利产品——丹红注射液，首当其冲，被梳理出至少在11个省(市)26次被预警(严格监控)、限制使用，甚至随时面临停用风险。
05
2015年平均每天花1600万元“推广”
据媒体报道，2016年年中，步长制药重启IPO，却被媒体爆出“天价推广费”——2013年至2015年的三年间，公司在“市场及学术推广”方面分别花去了44.66亿、51.83亿、58.41亿，累计达到154.9亿元，连续三年超过同期营业收入的一半以上。其中2015年，平均每天花1600万元用于“推广”。
据时代周报2016年报道，招股说明书显示，报告期内，“市场及学术推广费”占当年营业收入的比重超过了50%，是当期研发费用的20余倍。
声明：该文观点仅代表作者本人，搜狐号系信息发布平台，搜狐仅提供信息存储空间服务。
Big cat finance
1003 article
3.1 billion total reading
View TA's article >
1419
share to
The bottom step of the pharmaceutical financial empire: relying on the needle to dig the first bucket of gold, star medicine 26 times was warned
2019-05-03 08:25 beautiful / annual report / promotion
Source | Chongqing Morning News
A Chinese billionaire family spent $6.5 million to enroll their children at Stanford University. The media pointed out that the high-priced school attendance was for the school's student Zhao Yusi, whose father was Zhao Tao, chairman of Stephan Pharmaceuticals.
According to reports, Zhao Tao met with Singh, the manager of Morgan Stanley, and the counseling counselor of Singh, and then Zhao Tao paid $6.5 million to Singh. Zhao Yusi was admitted to Stanford University in 2017, majoring in psychology and East Asian studies. .
At the end of 2017, Singer forged information to give applicants a certificate of sailing and successfully entered Stanford University. After Zhao Yusi entered the school, Singh donated 500,000 US dollars for the sailing project, which can be arbitrarily controlled by sailing coach John Vandermore.
Stanford University has expelled Zhao Yusi at the end of March, and the coach has also been arrested. Currently Stanford University declined to comment on the incident. This is by far the largest number of college fraud cases in the United States.
On the 2nd, the media conducted a verification on the matter to Pu Xiaoping, vice president of the pharmaceutical company and secretary of the board of directors. Pu Xiaoping responded that he was studying the matter. He said that Buchang Pharmaceutical is “a normal company, and the major shareholder is not very relevant to us. The Shanghai Stock Exchange has not asked us yet, and everything is subject to the announcement."
01
The first bucket of gold for step entrepreneurship: giving Singapore patients a needle
According to public information, Zhao Tao is the chairman of Buchang Pharmaceutical Co., a 53-year-old Singaporean. He has been the chairman of the company since 2001. He is also a director of the step (Hong Kong), a director of Shoucheng International (Hong Kong) and a director of Dad Holdings. Waiting for a position.
Founded in 1993, Buchang Pharmaceutical was listed on November 18, 2016. It is a Shandong pharmaceutical company and a “family company”. It belongs to the father and son to start a business together. Zhao Buchang (famous cardiovascular disease expert, famous drug inventor, stepper brain heart inventor) is Zhao Tao's father, Zhao Chao (currently president of Buchang Pharmaceutical) is the second son of Zhao Buchang. Buchang Pharmaceutical is mainly engaged in the research and development, production and sales of proprietary Chinese medicines. The main products are in the field of traditional Chinese medicine for cardiovascular and cerebrovascular diseases, as well as other fields such as gynecological medication.
Zhao Buchang was born in 1942. After graduating from Xi'an Jiaotong University School of Medicine (formerly Xi'an Medical College), he responded to the call and voluntarily signed up to the Altay branch in Xinjiang on the border between China and the Soviet Union. In the summer of 1963, Zhao Buchang mobilized his wife Wu Haiqin to come to the deserted Gobi. After two 18 years of work in Xinjiang, they returned to the 215 Hospital of Xianyang Nuclear Industry Department to become an ordinary doctor. The four children of both of them were born in Xinjiang.
At that time, Zhao Buchang took stroke and coronary heart disease as the main direction of research, treated stroke hemiplegia, and created the theory of "medicine gas needle" therapy and "Heart and Heart Tongzhi". In 1992, he became an expert enjoying special allowances from the State Council.
Unlike many family businesses that "one generation fights the world and the second generation inherits the clothes", the earliest development of Buchang Pharmaceutical was created by the three fathers and sons of Zhao Buchang. The second generation is also a generation, that is, the father and son.
Born in 1966, Zhao Tao, like his parents Zhao Buchang and Wu Haiqin, was also a medical doctor. He graduated from Xi'an Medical University in 1989. Zhao Buchang's "medicine gas needle" technology for patients with cardiovascular and cerebrovascular diseases is actually the result of painstaking research by father and son. Where did the starting capital of Zhao’s father and son founded Buchang Pharmaceutical come from? This also has to say that a "Chinese god" is popular in Singapore.
In the winter of 1992, Zhao Tao and his father were invited to participate in the "International Symposium on Chinese Medicine and Acupuncture to the World" held in Singapore. During the meeting, the organizers specially arranged an on-site medical treatment for the Zhao family. At that time, a Singaporean female patient named Liu Yamei, who was in her 60s, had been in her for six years and could not move her legs at all.
Under the watchful eyes of the audience experts and reporters, Zhao Tao put a special medicine cap on the old man. After massaging the head for a while, he took out the silver needle and poked it on the acupoints of Liu Yamei's limbs...
After 20 minutes, the miracle appeared! Liu Yamei was able to grab the handrail and slowly stood up. The next day, Singapore's large and small newspapers published "Chinese God" successful medical treatment news, Zhao family and son became Singapore's well-known Chinese medicine celebrities. Should be requested, Zhao Tao stayed in Singapore to continue practicing medicine.
When Zhao Buchang came back from Singapore, he found that he was actually "optimized combination" by the unit! In February 1993, Zhao Buchang and his wife Wu Haiqin were both removed, and their "Brain Heart Pass" capsules for treating cardiovascular and cerebrovascular diseases also reached a critical period for scientific research.
In desperation, Zhao Buchang and his son Zhao Tao, who is far away in Singapore, called and decided to start their own business. On August 28, 1993, Buchang Pharmaceutical Co., Ltd. was established in Xianyang. The nature of the enterprise was “Sino-foreign joint venture”, and the starting capital was the 400,000 US dollars that Zhao Tao remitted. It turned out that three months of practicing medicine in Singapore, 27-year-old Zhao Tao made a full profit of 900,000 dollars.
In the second year of the business, the first exclusive patented drug product, “Step by Brain Heart Pass”, was put on the market. In the same year, it sold for 5 million yuan. After that, this “explosive model” product was rushing all the way. Today, it is related to the Olympics and the Tianshili. Compound Danshen Dripping Pills are among the top three brands of cardiovascular and cerebrovascular medicine.
On November 18, 2016, Buchang Pharmaceutical Co., Ltd., headquartered in Heze, Shandong, was listed on the Shanghai Stock Exchange. According to the market value of the day, the wealth of the Zhao family reached 24.478 billion yuan, becoming the richest person in Shandong.
02
Step family, "ten group", unsuccessful meal
As the eldest son of Zhao Buchang, Zhao Tao is the co-founder of Buchang Pharmaceutical. He was the manager of the company in Xianyang. He was the one who handled it. The logo of the step was drawn on a postcard sent to his father. Also left a sentence: one day, the world will remember it.
In the process of establishing the step, the big family Zhao Buchang was like the commander of the commander of the army. When he first started, he was actually the "two-person turn" between him and his eldest son Zhao Tao. When the company was on the scale, it began to recruit soldiers from the family members. ", expand the entrepreneurial team. The second son, Zhao Chao, is the current president of Buchang Pharmaceutical. After graduation, he worked as a production chief at the Yellow River Brewery. When his father shouted, he broke his iron rice bowl and participated. Also, the youngest daughter, Zhao Jing, is currently the chairman of the Shandong Danhong Pharmaceutical Group. She is also a doctor who quit her job.
Not only that, the daughters of Zhao Tao and Zhao Chao’s brothers, as well as the eldest daughter Zhao Wei and her sister Zhao Jing’s husband, also served in the step, a second generation formed the family “ten group”. Zhao Buchang, 55, said that we have no retreat. "If you don't succeed, you have to eat!"
After more than one year of listing, on December 11, Stephan Pharmaceutical, which was the "most expensive new stock" aura, fell below the issue price and became the first stock to break the issue price since the implementation of the new IPO in 2016. At the relative peak, the market value of Buchang Pharmaceutical evaporated nearly 70 billion yuan, and the wealth of the Zhao family was “shrinking”.
03
Four major products bring nearly 10 billion in revenue every year
The data show that the company's cardiovascular and cerebrovascular related products include Chinese patent medicine Danhong injection, Naoxintong capsule, Wenxin granules and chemical medicine Guhong injection. The total income in 2017 reached 9.944 billion yuan, with a growth rate of 11.76%. . The four major product treatments cover common cardiovascular and cerebrovascular diseases such as stroke, arrhythmia, insufficient blood supply and ischemic infarction.
Recently, Buchang Pharmaceutical disclosed its annual report for 2018. The company achieved operating income of 13.66 billion yuan last year, down 1.4% year-on-year, but the net profit attributable to shareholders of listed companies was 1.89 billion yuan, a year-on-year increase of 15.3%. In the first quarter of 2019, the company achieved a total operating income of 2.883 billion, an increase of 18.61% year-on-year; the net profit attributable to owners of the parent company was 284 million, an increase of 37.79%. Among them, the cardiovascular and cerebrovascular field in the 2018 revenue of nearly 11 billion yuan, accounting for more than 80%, gross margin of 85.16%, the company's four major cardiovascular and cerebrovascular drug products in 2018 total income of 9.143 billion yuan.
● According to the data, Stephan Pharmaceutical has developed breviscapine sodium chloride injection (exclusive production) in recent years. The treatment scope includes: ischemic cerebrovascular disease, such as cerebral infarction, hemiplegia caused by sequelae of cerebral hemorrhage; coronary heart disease, Angina, myocardial infarction and hyperviscosity; and other ischemic and microcirculatory disorders. The product's revenue in 2018 is 0.26 billion yuan.
● In the field of chemical medicine, the company has developed Glucosamine Injection for occlusive cerebrovascular disease and other ischemic vascular diseases. The income of this variety in 2018 was 284 million yuan.
● Compound brain peptide ganglioside injection (exclusive, patented variety) for the treatment of stroke, senile dementia, craniocerebral injury, spinal cord injury and traumatic peripheral nerve injury, for the treatment of dysfunction caused by brain diseases. The income of this variety in 2018 is 505 million yuan.
● Compound Quartz Injection (exclusive, patented variety) for the treatment of acute and chronic cerebrovascular diseases, senile dementia, craniocerebral trauma, spinal cord injury and other causes of central nervous system injury, peripheral nerve injury, cerebrovascular accident Nervous sequelae after trauma and trauma, and sequelae such as brain dysfunction caused by cerebrovascular disease; used to treat edema caused by occlusion syndrome, arteriosclerosis, thrombophlebitis, capillary hemorrhage, and elevated vascular permeability. The income of this variety in 2018 is 355 million yuan.
● Ginkgo biloba oral solution (exclusive, patented variety), mainly used for coronary heart disease, angina pectoris, ischemic cerebrovascular disease, can improve heart and cerebral ischemic symptoms. The income of this variety in 2018 was 279 million yuan.
04
Danhong injection has been listed as key monitoring for 26 times.
According to the media reported in April 2018, Buhong Pharmaceutical's Danhong injection (selling 60 yuan a) was frequently listed as a key monitoring due to frequent serious adverse reactions, and even faced the risk of suspension at any time.
According to the prospectus before the listing of Stephan Pharmaceutical, the annual sales amount of Danhong Injection was as high as 4.161 billion, 3.831 billion and 3.36 billion, totaling 11.352 billion from 2013 to 2015. The proportion of revenue is over 30%, and the proportion of profit is more than 40%.
According to the report, the list of Chinese medicines in the list of key monitoring drugs and auxiliary medicines issued by 19 provinces and 15 cities accounted for nearly 40%, of which 90% were Chinese medicine injections. Stephan Pharmaceutical's exclusive patented product, Danhong Injection, bears the brunt of it and is sorted out at least 11 provinces (cities) for 26 warnings (strictly monitored), restricted use, and even at risk of decommissioning at any time.
05
In 2015, the average daily spending of 16 million yuan "promotion"
According to media reports, in the middle of 2016, Buchang Pharmaceutical restarted the IPO, but it was exploded by the media with “astronomical promotion fee”. During the three years from 2013 to 2015, the company spent 44.66 on “market and academic promotion”. 100 million yuan, 5.183 billion yuan, 5.941 billion yuan, a total of 15.49 billion yuan, more than half of the operating income for the third consecutive year. In 2015, an average of 16 million yuan was spent on “promotion” every day.
According to the Times Weekly report in 2016, the prospectus shows that during the reporting period, “market and academic promotion fees” accounted for more than 50% of the operating income of the year, and more than 20 times of the current research and development expenses.
Go back to Sohu and see more
Disclaimer: This article only represents the author himself, Sohu is the information publishing platform, and Sohu only provides information storage space services.
